You and me three my friend. Maybe they are waiting
Post# of 36566
(Total Views: 317)
Posted On: 03/13/2020 3:00:54 PM
You and me three my friend. Maybe they are waiting for everyone to pass away and then come to market, because you know we really react fast to changing environments.
Maybe Joe's new friend, docj, will be kind enough to email him the 2/6/2020 press release and highlight:
"About our Rapid Diagnostic Testing Technology:
NuGenerex Diagnostics (NGDx) has developed the Express II, an innovative, patent-pending,
point-of-care rapid diagnostic platform. The proprietary Express II kit design is complex enough
to detect a wide range of analytes including antigens, antibodies, or protein biomarkers that are
found in infectious diseases, cancer, metabolic diseases and a host of other medical conditions.
Though complex, the Express II issimple enough to be performed in the physician’s office or even
at home by consumers.
Using the Express II platform, NGDx has developed point-of-care rapid diagnostic tests for HIV,
Hepatitis B Hepatitis C, Tuberculosis, Syphilis and three Malaria-specific assays. Our syphilis
assay, The Express II Syphilis Treponemal Assay, which has been has been approved for
commercialization in Europe through the European CE Marking regulatory process, is a rapid
point-of-care diagnostic assay for the detection of syphilis antibodies in primary and secondary
syphilis with an accuracy equal to or better than standard laboratory assays for syphilis, with
sensitivities and specificities of over 99%.
The Express II diagnostic platform has major advantages over other point-of-care devices
because of its simplicity of use, which include fewer steps of operation, the elimination of loops
or pipettes for transferring samples, the elimination of unnecessary sample pickup pads, and its
ability to be utilized in office settings, remote field use and for individual in-home use directly by
consumers who can conduct the test by themselves in privacy. The results of
any assay conducted using the Express II platform are available in 15-20 minutes, allowing
clinical and therapeutic decisions to be made immediately and, if positive, appropriate patient
counseling can be initiated on site.
Currently, NGDx is initiating a project to adopt the Express II platform in the development of a
diagnostic point-of-care test for the rapid diagnosis of the novel Wuhan Coronavirus (2019
nCoV) infection which has been declared a worldwide public health emergency by the World
Health Organization. This test will allow the detection of the Wuhan Coronavirus directly in
respiratory samples taken from the nose and throat of individuals and can be used for screening
of travelers at national border entry points, or for direct diagnosis of suspected infected persons
with symptoms, with results available in 15-20 minutes. It requires minimum training and can be
used by national security agents, airline employees and any other appropriate authorized
individual in all commercial and medical settings."
Maybe Joe's new friend, docj, will be kind enough to email him the 2/6/2020 press release and highlight:
"About our Rapid Diagnostic Testing Technology:
NuGenerex Diagnostics (NGDx) has developed the Express II, an innovative, patent-pending,
point-of-care rapid diagnostic platform. The proprietary Express II kit design is complex enough
to detect a wide range of analytes including antigens, antibodies, or protein biomarkers that are
found in infectious diseases, cancer, metabolic diseases and a host of other medical conditions.
Though complex, the Express II issimple enough to be performed in the physician’s office or even
at home by consumers.
Using the Express II platform, NGDx has developed point-of-care rapid diagnostic tests for HIV,
Hepatitis B Hepatitis C, Tuberculosis, Syphilis and three Malaria-specific assays. Our syphilis
assay, The Express II Syphilis Treponemal Assay, which has been has been approved for
commercialization in Europe through the European CE Marking regulatory process, is a rapid
point-of-care diagnostic assay for the detection of syphilis antibodies in primary and secondary
syphilis with an accuracy equal to or better than standard laboratory assays for syphilis, with
sensitivities and specificities of over 99%.
The Express II diagnostic platform has major advantages over other point-of-care devices
because of its simplicity of use, which include fewer steps of operation, the elimination of loops
or pipettes for transferring samples, the elimination of unnecessary sample pickup pads, and its
ability to be utilized in office settings, remote field use and for individual in-home use directly by
consumers who can conduct the test by themselves in privacy. The results of
any assay conducted using the Express II platform are available in 15-20 minutes, allowing
clinical and therapeutic decisions to be made immediately and, if positive, appropriate patient
counseling can be initiated on site.
Currently, NGDx is initiating a project to adopt the Express II platform in the development of a
diagnostic point-of-care test for the rapid diagnosis of the novel Wuhan Coronavirus (2019
nCoV) infection which has been declared a worldwide public health emergency by the World
Health Organization. This test will allow the detection of the Wuhan Coronavirus directly in
respiratory samples taken from the nose and throat of individuals and can be used for screening
of travelers at national border entry points, or for direct diagnosis of suspected infected persons
with symptoms, with results available in 15-20 minutes. It requires minimum training and can be
used by national security agents, airline employees and any other appropriate authorized
individual in all commercial and medical settings."
(0)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Disclaimer: Of course, all of this is my opinion and you should not make any investment decisions based on my opinion. I have not received any non-public information.